Lymphoma Clinical Trials and Research

Clinical Trials Questions?

877-338-7425

The goal of the Lymphoma Program's clinical research effort is to make the treatment of lymphoid malignancies more effective and specific, while also less toxic. Toward that goal, the program makes promising new therapies available to patients with a variety of lymphoid malignancies, in a carefully monitored setting, through clinical trials.

Current research focuses on targeting tumors with drugs directed against specific molecular targets in lymphoid malignancies, or with antibodies reactive against tumor cell surface proteins, alone or linked to radionucleotides. Another target of therapy is the tumor's "microenvironment" using inhibitors of angiogenesis (new blood vessel development) and stimulators of the immune response. Our team is also leading several clinical trials of CAR T-cell therapy for lymphoma.

Many members of the clinical research team also have active programs of laboratory-based investigation in lymphoid malignancies. Researchers work closely with other scientists within Harvard Medical School-affiliated institutions.

Featured Clinical Trials

Trial 22-702: A phase 2 study of epcoritamab and rituximab for first-line treatment of follicular lymphoma 
Principal Investigator: Reid Merryman, MD

Trial 22-632: A phase 2 study of glofitamab and obinutuzumab for first-line treatment of follicular lymphoma and marginal zone lymphoma 
Principal Investigator: Reid Merryman, MD

Trial 22-606: A phase 2 study of glofitamab plus polatuzumab-R-CHP for high-risk diffuse large B-cell lymphoma 
Principal Investigator: Jennifer Crombie, MD

Trial 22-378: A phase 2 study of magrolimab and pembrolizumab in relapsed or refractory classic Hodgkin lymphoma
Principal Investigator: Reid Merryman, MD

Trial 22-248: A phase 1 multicenter study of ruxolitinib and duvelisib in relapsed or refractory T- or NK-cell lymphomas
Principal Investigator: Eric Jacobsen, MD

Trial 22-121: A phase 2 study of brentuximab vedotin plus nivolumab without stem cell consolidation in patients with relapsed classical Hodgkin lymphoma
Principal Investigator: Philippe Armand, MD, PhD

Trial 21-204: A phase 2 multi-cohort trial of ipilimumab with and without nivolumab in patients with relapsed/refractory classic Hodgkin lymphoma
Principal Investigator: Reid Merryman, MD

Trial 21-040: A phase 1/2 study of acalabrutinib, venetoclax, and obinutuzumab (AVO) in patients with relapsed/refractory and previously untreated mantle call lymphoma
Principal Investigator: Austin Kim, MD